Question · Q3 2025
Noah inquired about the strategic timing and customer feedback for Natera's expanded 20-gene Fetal Focus panel, including its reimbursement outlook, and then shifted to Signatera's path to NCCN guidelines and broader commercial payer adoption following recent ESMO and Invigor data.
Answer
CEO Steve Chapman highlighted positive customer feedback on the initial 5-gene panel and the planned expansion, emphasizing the EXPAND clinical trial as a gold standard. General Manager of Oncology and Chief Medical Officer Alex Aleshin and President of Clinical Diagnostics Solomon Moshkevich discussed the Invigor 011 data's Level 1A status, its submission for FDA approval, and the expectation for NCCN guideline inclusion by mid-to-late next year. CFO Michael Brophy noted early traction with commercial payers due to biomarker bills and the strong clinical evidence.
Ask follow-up questions
Fintool can predict
NTRA's earnings beat/miss a week before the call